

Amendments to the Specification:

Please replace paragraph [05] with the following amended paragraph:

--The present invention provides methods of inducing apoptosis in a cancer cell. In some embodiments, the method comprises contacting the cell with (i.) an anti-DR4 or anti-DR5 affinity agent agonist; and (ii.) an apoptosis-inducing agent. In some embodiments, the agonist is an anti-DR-5 antibody. In some embodiments, the anti-DR5 antibody has the binding specificity of an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35. In some embodiments, the anti-DR5 antibody comprises a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35. In some embodiments, the anti-DR5 antibody is Antibody A (ATCC Deposit No. ____). In some embodiments, the agonist is an anti-DR4 antibody.--

Please replace paragraph [15] with the following amended paragraph:

--In some embodiments, the agonist and the agent are administered separately. In some embodiments, the agonist and the agent are administered as a mixture. In some embodiments, the agonist is an anti-DR-5 antibody. In some embodiments, the anti-DR5 antibody has the binding specificity of an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35. In some embodiments, the anti-DR5 antibody comprises a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35. In some embodiments, the anti-DR5 antibody is Antibody A (ATCC Deposit No. ____). In some embodiments, the agonist is an anti-DR4 antibody. In some embodiments, the cell is contacted with an anti-DR4 antibody agonist and an anti-DR5 antibody agonist.--

Please replace paragraph [20] with the following amended paragraph:

--The present invention also provides a physiological composition comprising a therapeutically effective amount of (i.) an anti-DR4 or anti-DR5 antibody agonist; and (ii.) an apoptosis-inducing agent. In some embodiments, the agonist is an anti-DR-5 antibody. In some embodiments, the anti-DR5 antibody has the binding specificity of an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35. In some embodiments, the anti-DR5 antibody comprises a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35. In some embodiments, the anti-DR5 antibody is Antibody A (ATCC Deposit No. _____). In some embodiments, the agonist is an anti-DR4 antibody. In some embodiments, the cell is contacted with an anti-DR4 antibody agonist and an anti-DR5 antibody agonist.--

Please replace paragraph [26] with the following amended paragraph:

--The present invention also provides methods of inducing apoptosis in a cancer cell comprising contacting the cell with an affinity agent with the binding specificity of an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35. In some embodiments, the agonist is an anti-DR-5 antibody. In some embodiments, the anti-DR5 antibody has the binding specificity of an antibody comprising a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35. In some embodiments, the anti-DR5 antibody comprises a heavy chain variable region comprising the sequence displayed in Figure 24 or Figure 35 and a light chain variable region as displayed in Figure 25 or Figure 35. In some embodiments, the anti-DR5 antibody is Antibody A (ATCC Deposit No. _____).--

Please replace paragraph [101] with the following amended paragraph:

--Exemplary anti-DR5 antibodies include those with the specificity of an antibody comprising the light and heavy chain variable region sequences displayed in Figures 24 and 25. In some embodiments, the antibody is Antibody A (ATCC Deposit No. _____).--

Please replace paragraph [468] with the following amended paragraph:

--Figure 3 displays a dose response analysis. The 3 antibody agonists show different dose responses relative to Jurkat cell killing. Antibody A (ATCC Deposit No. _____) had the best potency and thus was chosen for further studies. Imgenex-257 is a DR5 specific antibody that has no functional activity.--